×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XFOR – x4 pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XFOR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
08:02 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $10.00 price target on by analysts at Stifel Nicolaus.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $10.00 price target on by analysts at Stifel Nicolaus.
12/2
03:47 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/1
09:15 am
xfor
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia [Seeking Alpha]
High
Report
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia [Seeking Alpha]
11/29
07:17 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
High
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/25
02:00 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/22
02:11 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by analysts at Wall Street
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by analysts at Wall Street
11/19
01:23 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:46 pm
xfor
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: Nantahala Capital Management, LLC
Neutral
Report
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: Nantahala Capital Management, LLC
11/7
11:14 am
xfor
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: FMR LLC
High
Report
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: FMR LLC
11/5
08:25 am
xfor
Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30
Medium
Report
Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30
11/5
08:06 am
xfor
Form 8-K X4 Pharmaceuticals, Inc For: Nov 05
Medium
Report
Form 8-K X4 Pharmaceuticals, Inc For: Nov 05
11/3
04:10 pm
xfor
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC
Low
Report
Form SCHEDULE 13G X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC
10/31
04:42 pm
xfor
Form 4 X4 Pharmaceuticals, Inc For: Oct 29 Filed by: KIRSKE DAVID
Neutral
Report
Form 4 X4 Pharmaceuticals, Inc For: Oct 29 Filed by: KIRSKE DAVID
10/31
04:42 pm
xfor
Form 4 X4 Pharmaceuticals, Inc For: Oct 29 Filed by: Volpone John
Neutral
Report
Form 4 X4 Pharmaceuticals, Inc For: Oct 29 Filed by: Volpone John
10/31
04:42 pm
xfor
Form 4 X4 Pharmaceuticals, Inc For: Oct 29 Filed by: Craig Adam R
Neutral
Report
Form 4 X4 Pharmaceuticals, Inc For: Oct 29 Filed by: Craig Adam R
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating.
33.7%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
TOP News Decliners
3/20
Form 8-K X4 Pharmaceuticals, Inc For: Mar 18
-29.5%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: